TCT - 2017

David J. Cohen, MD, MSc is currently Director of Clinical and Outcomes Research at the Cardiovascular Research Foundation (New York, NY) and Director of Academic Affairs at St. Francis Hospital (Roslyn, NY). Previously, he was Professor of Medicine at the University of Missouri–Kansas City and Director of Cardiovascular Research and Medical Director of Health Economics and Technology Assessment at Saint Luke’s Mid America Heart Institute. Heart Institute where he continues to direct the Health Economics and Technology Assessment Group. Dr. Cohen earned his M.D. at Harvard Medical School and his Master's degree in Health Policy at the Harvard School of Public Health. He did his clinical training at Brigham and Women's Hospital and was a clinical and research fellow in cardiology at Beth Israel Hospital for five years. Dr. Cohen is a practicing interventional cardiologist with a focus on structural and valvular heart disease. His research focuses on the application of formal cost-effectiveness methodology to novel interventions for cardiovascular disease (CVD), the extension of traditional cardiovascular outcomes research to include patient-centered outcomes, and the development and evaluation of instruments for assessing CVD patients’ health status and preferences. He is also active in research to determine the short- and long-term outcomes of new devices for percutaneous coronary revascularization and identifying the optimal target populations and techniques for these devices. Dr. Cohen has published more than 500 original articles in leading journals, including the New England Journal of Medicine, Lancet, JAMA, Circulation, and the Journal of the American College. Dr. Cohen serves on the editorial board for the American Heart Journal, JACC Interventions, and Circulation and reviews for the American Journal of Cardiology, Journal of the American College of Cardiology, New England Journal of Medicine, JAMA, and Medical Decision Making.

A consultant cadiologist at Maasstad Ziekenhuis, Rotterdam, Netherlands. Features in 3 videos on Wondr Medical. Elvin Kedhi generally speaks on Primary Percutaneous Coronary Intervention (PPCI), Ischemia, Infarction, Cardioprotection, Anti-Platelet Drugs , Thrombosis, Bleeding, and Acute Coronary Syndromes (ACS).

Emmanouil S. Brilakis, MD, PhD, FACC, FAHA, FESC, FSCAI is Director of the Center for Complex Coronary Interventions at the Minneapolis Heart Institute and Chairman of the Center for Coronary Artery Disease at the Minneapolis Heart Institute Foundation. After graduating from Lycee Leonin de Patissia, Dr. Brilakis received his medical degree from the National Kapodistrian University of Athens, Greece. He trained in Internal Medicine, Cardiovascular Diseases and Interventional Cardiology at the Mayo Clinic. He also completed a Masters in Clinical Research at the Mayo Clinic and a PhD in Clinical Research at the National Kapodistrian University of Athens, Greece. He served as director of the cardiac catheterization laboratories at VA North Texas Health Care System from 2004-2016. He was on the faculty of the University of Texas Southwestern Medical School from 2004-2018. Dr. Brilakis leads a large clinical trial group investigating treatment of chronic total occlusions, prevention and treatment of saphenous vein graft disease, prevention and management of complications, intracoronary imaging, antiplatelet treatment optimization post coronary stenting, radiation safety in the catheterization laboratory, and implementation of novel technologies in healthcare. Dr. Brilakis has authored or co-authored over 600 manuscripts and has written the Manual of CTO Interventions, now in its second edition. He directs the Complex Coronary Interventions Webcast series and is on the Board of the Cardiovascular Innovations Foundation. He is an associate editor for Circulation and an editorial board member and reviewer for several journals and grant agencies. He is lecturing and proctoring at several institutions in the United States and abroad.

Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine (Cardiology) and Professor of Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 120 national and international multicenter randomized trials (many of which have led to new device approval or indications in the US), has authored more than 2000 manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. With a 2018 H-factor of 152, Dr. Stone was recently listed in Nature Medicine as one of the most prolific authors in science. Dr. Stone's areas of expertise include interventional therapies of acute coronary syndromes, myocardial infarction and cardiogenic shock; drug-eluting stents and bioresorbable scaffolds; left main and complex coronary artery disease intervention; antiplatelet and antithrombotic pharmacotherapies; transcatheter valve repair and replacement; interventional hypertension and heart failure therapies; left atrial appendage closure; intravascular imaging (IVUS, OCT and NIRS); vulnerable plaque diagnosis and treatment; adjunctive interventional devices including atherectomy, distal embolic protection, thrombectomy, covered stents, chronic total occlusion devices, and brachytherapy; saphenous vein graft therapies; contrast nephropathy; clinical trial design; and regulatory issues. Dr. Stone is the director of TCT, the world's largest symposium devoted to interventional cardiology and vascular medicine. Dr. Stone founded the annual National Interventional Cardiology Fellow's Course and Transcatheter Valve Therapies TVT), the Chronic Total Occlusion (CTO) Summit, and co-directs multiple other meetings in the US, China, Russia, Europe, S. Korea and elsewhere.

Consultant Interventional Cardiologist and Revascularisation Group Chair at Royal Brompton Hospital, London. His clinical focus is on use of intravascular imaging in complex PCI , CTO and cardiogenic shock. His clinical research interests focus on optical coherence tomography, calcific coronary disease and percutaneous ventricular support. Dr Hill was global co-chief investigator for the DISRUPT CAD III study and has served as UK principal investigator for multiple interventional trials. He has served as a CTO and complex PCI proctor on a global basis and works closely with OPTIMA to focus on the development of OPTIMAL PCI. He is the founding co-director of the Complete Revascularisation (CoRe) meetings held every year in London.

Josep Rodes-Cabau is an interventional cardiologist at Québec Heart and Lung Institute, Quebec, QC, Canada.

José Henriques is a consultant cardiologist at Academic Medical Center, Amsterdam, The Netherlands.

Mayra Guerrero works at Evanston Hospital, Evanston, IL, USA.

Works at Deutsches Herzzentrum Muenchen, Munich, Bayern, Germany. Features in 13 videos on Wondr Medical. Michael Joner generally speaks on Stents, Drug Eluting Stents (DES), Peripheral Vascular Disease (PVD), Intravascular Ultrasound (IVUS), and Coronary Optical Coherence Tomography (OCT).

Olivier Varenne is an interventional cardiology at Hôpital Saint-Vincent-de-Paul, Paris, France.

Dr Rasha Al-Lamee is an Interventional Cardiology Consultant at Imperial College Healthcare NHS Trust in London, UK. Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is the lead author of the primary publication in The Lancet. At Imperial College, she is actively involved in the development and recruitment for a number of multi-centre clinical trials. Dr Al- Lamee has over 40 peer-reviewed publications and has presented at international Cardiology conferences worldwide throughout her clinical career. She studied at the University of Oxford and University College London. She went onto complete her training as a junior doctor on the Barts and the London Medical rotation before being appointed as a Specialist Registrar on the North West London Cardiology rotation in 2006. Dr Al-Lamee has twelve years of Cardiology experience and completed three years of Interventional Fellowship training at Hammersmith Hospital in London. She also spent a year training as an Interventional Fellow under the supervision of Professor Antonio Colombo in Milan. She completed specialist training in Cardiology in 2013.

A consultant cadiologist at Uppsala University, Uppsala, Sweden. Features in 1 video on Wondr Medical. Stefan James generally speaks on Coronary Interventions, Anti-Platelet Drugs , and Stable Coronary Artery Disease (CAD).